Alignment Healthcare, Inc. Announces $330 Million Convertible Senior Notes Offering
Alignment Healthcare, Inc. Announces $330 Million Convertible Senior Notes Offering
Alignment Healthcare plans to issue $330 million in Convertible Senior Notes to refinance debt and support corporate efforts.
Quiver AI Summary
Alignment Healthcare, Inc. has announced its intention to issue $330 million in 4.25% Convertible Senior Notes due in 2029 through private agreements with investors, expected to close on November 22, 2024. The company plans to use the net proceeds of approximately $321.05 million primarily to repay its existing term loan and for general corporate purposes. The Notes, which will mature on November 15, 2029, have a conversion price set at approximately $16.04, reflecting a 25% premium to the company's stock price as of November 14, 2024. Additionally, the placement agent intends to purchase about 3.442 million shares of the company's stock in connection with this transaction. The announcement clarifies that no securities are being sold or offered in jurisdictions where such offers are illegal, and the Notes have not been registered under applicable securities laws.
Potential Positives
- The Company is raising $330 million through the issuance of 4.25% Convertible Senior Notes, providing significant capital for strategic initiatives.
- The net cash proceeds of approximately $321.05 million will be used to reduce the cost of capital by repaying a more expensive existing term loan facility.
- The offering indicates investor confidence, as evidenced by the interest in the Convertible Senior Notes and the associated stock purchases planned by the placement agent.
- The conversion price of the Notes reflects a 25% premium over the current stock price, suggesting a positive market outlook for the Company's stock.
Potential Negatives
- The company is increasing its debt burden by issuing $330 million in Convertible Senior Notes, which could lead to higher financial risk if the company's earnings do not improve as anticipated.
- The conversion price of the Notes represents a premium of 25% to the closing stock price, potentially indicating a lack of confidence in the stock's current valuation among investors.
- The plan to use proceeds to repay a high-interest term loan suggests financial distress or pressure to manage existing debt levels more effectively.
FAQ
What is the amount of the convertible senior notes issued by Alignment Healthcare?
Alignment Healthcare announced it will issue $330 million principal amount of convertible senior notes.
What is the maturity date for the notes issued by Alignment Healthcare?
The convertible senior notes will mature on November 15, 2029, unless converted earlier.
What will Alignment Healthcare do with the proceeds from the notes?
The proceeds will be used to repay existing term loans and for general corporate purposes.
What is the interest rate on the convertible senior notes?
The convertible senior notes will have an interest rate of 4.25% payable semi-annually.
How does the new financing affect Alignment Healthcare's stock?
The placement agent may purchase common stock, potentially influencing the market price of the stock and notes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALHC Insider Trading Activity
$ALHC insiders have traded $ALHC stock on the open market 59 times in the past 6 months. Of those trades, 0 have been purchases and 59 have been sales.
Here's a breakdown of recent trading of $ALHC stock by insiders over the last 6 months:
- ROBERT THOMAS FREEMAN (Chief Financial Officer) has traded it 17 times. They made 0 purchases and 17 sales, selling 426,500 shares.
- JOSEPH S KONOWIECKI has traded it 8 times. They made 0 purchases and 8 sales, selling 123,333 shares.
- JOHN E KAO (Chief Executive Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 270,000 shares.
- HAKAN KARDES (Chief Experience Officer) has traded it 4 times. They made 0 purchases and 4 sales, selling 75,000 shares.
- DAWN CHRISTINE MARONEY (President, Markets) has traded it 12 times. They made 0 purchases and 12 sales, selling 250,000 shares.
- HYONG KIM (Chief Medical Officer) sold 22,460 shares.
- CHRISTOPHER J JOYCE (Chief Legal and Admin. Officer) has traded it 11 times. They made 0 purchases and 11 sales, selling 74,467 shares.
- JEFFREY H MARGOLIS has traded it 3 times. They made 0 purchases and 3 sales, selling 3,600 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALHC Hedge Fund Activity
We have seen 68 institutional investors add shares of $ALHC stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DURABLE CAPITAL PARTNERS LP added 3,980,949 shares (+inf%) to their portfolio in Q2 2024
- MILLENNIUM MANAGEMENT LLC removed 3,146,691 shares (-64.7%) from their portfolio in Q2 2024
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 2,630,788 shares (+31.8%) to their portfolio in Q2 2024
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,443,795 shares (-30.4%) from their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,258,648 shares (+2403.5%) to their portfolio in Q3 2024
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,131,974 shares (-36.5%) from their portfolio in Q3 2024
- FIRST TRUST ADVISORS LP added 531,998 shares (+668.0%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ORANGE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) (the "Company") today announced that it has entered into privately negotiated subscription agreements with certain investors, pursuant to which it will issue $330 million principal amount of 4.25% Convertible Senior Notes due 2029 (the "Notes"). The issuance of the Notes is expected to close on November 22, 2024, subject to customary closing conditions.
The Notes will be senior, unsecured obligations of the Company, and interest will be payable semi-annually in arrears at a rate of 4.25% per annum. The Notes will mature on November 15, 2029, unless earlier repurchased, redeemed or converted in accordance with their terms. The conversion price for the Notes will initially be approximately $16.04, which represents a premium of 25% to the closing price of the Company's common stock on November 14, 2024.
The Company anticipates the net cash proceeds from the issuance of the Notes will be approximately $321.05 million, after subtracting fees, discounts, and estimated expenses in connection with the transaction. The Company intends to use the proceeds to lower its cost of capital by repaying the Company's existing term loan facility, which bears interest at SOFR + 6.5%, and for general corporate purposes.
In connection with the issuance of the Notes, the Company has been advised that the placement agent for the Notes intends to purchase approximately 3.442 million shares of the Company's common stock in privately negotiated transactions from certain purchasers of the Notes through a financial intermediary at a discount to the last reported sale price of the Company's common stock on November 14, 2024. Such purchases by the placement agent of the Company's common stock could increase (or reduce the size of any decrease in) the market price of the common stock or the Notes.
Additional information regarding this announcement may be found in a Current Report on Form 8-K that the Company intends to file with the U.S. Securities and Exchange Commission (the "SEC").
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of Company common stock, if any, issuable upon conversion of the Notes) and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.
The Notes and any shares of common stock issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as amended, or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Alignment Healthcare
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements concerning the estimated net proceeds of the offering, the anticipated use of such net proceeds and the expected closing of the offering. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor; changes in laws and regulations applicable to our business model; risks related to our indebtedness, including the potential for rising interest rates; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. There can be no assurance that the Company will be able to complete the offering on the anticipated terms, or at all. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2023, and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.
Investor Contact
Harrison Zhuo
hzhuo@ahcusa.com
Media Contact
Priya Shah
mPR, Inc. for Alignment Healthcare
alignment@mpublicrelations.com